

## CONFLICT-OF-INTEREST STATEMENT

**ECRG2 enhances the anticancer effects of cisplatin in cisplatin-resistant esophageal cancer cells via up-regulation of p53 and down-regulation of PNCA**

Xin-Fang Hou<sup>1</sup>, Lin-Ping Xu<sup>2</sup>, Hai-Yan Song<sup>3</sup>, Shuai Li<sup>1</sup>, Chen Wu<sup>1</sup>, Ju-Feng Wang<sup>1</sup>

1. Department of Medical oncology, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China; 2. Department of Science and Research, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China; 3. Key Laboratory for Medical Tissue Regeneration of Henan Province, College of Basic Medicine, Xinxiang Medical University, Xinxiang, China

**Conflict of Interest:** There are no conflicts of interest in relation to this manuscript.

*Ju-feng Wang.*

Ju-Feng Wang, MD, Professor,

Department of Medical oncology, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, 127 Dongming Road, Zhengzhou 450008, China.

Email: 13783583966@163.com

Telephone: +86-371-65587598

Fax: +86-371-65587598